How is Mitochondrial Dysfunction, Genetic Protein Maladaptation and Bioenergetic Collapse seen in Neurodevelopmental and Psychiatric Disorders ill-suited for Traditional Mental Health Care?

Mitochondrial Bioenergetics in Neurodevelopmental and Psychiatric Disorders

Mitochondrial dysfunction, genetic protein maladaptation, and bioenergetic collapse converge across neurodevelopmental and psychiatric disorders as shared pathophysiological mechanisms that traditional symptom-based mental health care does not address (Pei & Wallace, 2017; Bülow et al., 2022; Nunes et al., 2025). The brain's disproportionate energy demand — consuming up to 20% of the body's oxygen and 25% of its glucose despite representing 2–3% of body mass — makes it the organ most vulnerable to even partial mitochondrial defects (Pei & Wallace, 2017; Cuperfain et al., 2018; Anitha et al., 2023). People with neurodevelopmental disorders most often receive symptomatic treatment rather than interventions targeting underlying bioenergetic causes (Bülow et al., 2022).

Genetic and Protein-Level Mechanisms

Partial mitochondrial defects from heteroplasmic mtDNA mutations or heterozygous nuclear gene mutations can reduce bioenergetic output below the brain's functional threshold, predisposing to disorders ranging from autism to schizophrenia (Pei & Wallace, 2017). Mitochondrial protein synthesis by the 55S ribosome is the rate-limiting step in electron transport chain assembly, and genetic defects disrupting this machinery cause a phenotypic spectrum from autism to neurodegeneration (Bülow et al., 2022). Dysregulated mitochondrial protein synthesis is proposed as a chief yet understudied causative mechanism of neurodevelopmental and behavioral disorders (Bülow et al., 2022).

Nuclear-mitochondrial mismatch, pseudogene dysregulation, and microRNA-mediated disruption of mitochondrial gene expression further contribute to psychiatric disease phenotypes, particularly in schizophrenia and bipolar disorder (Cuperfain et al., 2018). Specific genetic syndromes illustrate this convergence: Fragile X syndrome involves Fmr1 deletion causing altered mitochondrial respiratory capacity and ROS accumulation (Yang et al., 2025), while Down, Rett, and Fragile X syndromes share lower brain ATP, elevated lactate, and abnormal respiratory chain complex activity despite differing genetic origins (Valenti & Vacca, 2023).

Bioenergetic Collapse Across Disorders

Disorder	Key Bioenergetic Finding	Citation
Autism (ASD)	Elevated lactate (17%), pyruvate (41%), abnormal ATP and mtDNA copy number	(Frye et al., 2024)
Schizophrenia	Reduced complex I (18–35%) and complex IV (22–28%) in prefrontal cortex; 20–22% ATP reduction	(Ricci et al., 2026)
Major depression	Decreased ATP, increased ROS, decreased antioxidant defense in all stress models	(Payares et al., 2024)
Bipolar disorder	mtDNA deletions in brain; altered mitochondria-related gene expression	(Ni et al., 2022)

Disorder	Key Bioenergetic Finding	Citation
Mitochondrial disease	54% lifetime psychiatric comorbidity (MDD, BD, anxiety, psychosis)	(Tanaka et al., 2022; Payares et al., 2024)

Bioenergetic impairment in schizophrenia is present in antipsychotic-naïve first-episode patients, establishing mitochondrial dysfunction as primary pathophysiology rather than a medication side effect (Ricci et al., 2026). A developmental vulnerability model posits that individuals with marginal mitochondrial capacity function adequately until adolescent brain maturation — with its massive energy demands from synaptic pruning and myelination — exceeds available resources, triggering cascading dysfunction (Ricci et al., 2026). Mitochondrial dysfunction may be an early upstream causal event rather than a downstream consequence in neurodevelopmental disorders (Valenti & Vacca, 2023; Anitha et al., 2023).

Why Traditional Care Falls Short

Current antipsychotic medications effectively treat positive symptoms in schizophrenia but poorly address negative and cognitive symptoms rooted in bioenergetic deficits (Ni & Chung, 2020; Ricci et al., 2026). Many antipsychotic treatments themselves carry metabolic side effects, compounding the underlying bioenergetic pathology they fail to correct (Ni et al., 2022). There is currently no cure for mitochondrial diseases, and treatment remains limited to symptom-relieving or progression-delaying measures that vary patient to patient (Tanaka et al., 2022).

- **Symptom-based frameworks** treat neurotransmitter imbalances while leaving oxidative phosphorylation deficits, mitochondrial fragmentation, and ROS accumulation unaddressed (Nunes et al., 2025).
- **Polygenic complexity** of neurodevelopmental disorders creates challenges for proper treatment, as the underlying cause of the majority of conditions remains unknown (Bülow et al., 2022).
- **Inconsistent characterization** across disorders — some studies examine mitophagy, others respiratory capacity, others network morphology — h identification of shared mechanisms (Ortiz-González, 2021).
- **Stress sensitivity** means individuals with subclinical mitochondrial defects are highly vulnerable to stress-induced neurological symptoms, a dimension traditional care does not assess or target (Pei & Wallace, 2017).

Multiple neuropsychiatric diseases may be treatable by a finite number of bioenergetics interventions, and even mild perturbations of mitochondrial function could produce marked clinical improvement through nuclear gene expression phase shifts (Pei & Wallace, 2017). Precision approaches using patient-specific iPSC models, multiomics profiling, and early mitochondrial biomarkers are proposed to move beyond symptom management toward interventions that address the bioenergetic roots of these disorders (Yang et al., 2025; Nunes et al., 2025).

References

Anitha, A., Thanseem, I., Iype, M., & Thomas, S. V. (2023). Mitochondrial dysfunction in cognitive neurodevelopmental disorders: Cause or effect?. *Mitochondrion*. https://doi.org/10.1016/j.mito.2023.01.002

Bülow, P., Patgiri, A., & Faundez, V. (2022). Mitochondrial protein synthesis and the bioenergetic cost of neurodevelopment. *iScience, 25*. https://doi.org/10.1016/j.isci.2022.104920

Cuperfain, A. B., Zhang, Z., Kennedy, J., & Gonçalves, V. (2018). The Complex Interaction of Mitochondrial Genetics and Mitochondrial Pathways in Psychiatric Disease. *Molecular Neuropsychiatry, 4*, 52 - 69. https://doi.org/10.1159/000488031

Frye, R. E., Rincón, N., McCarty, P. J., Brister, D., Scheck, A. C., & Rossignol, D. (2024). Biomarkers of mitochondrial dysfunction in autism spectrum disorder: A systematic review and meta-analysis.. *Neurobiology of disease*, 106520. https://doi.org/10.1016/j.nbd.2024.106520

Ni, P., Y., & Chung, S. (2022). Mitochondrial dysfunction in psychiatric disorders. *Schizophrenia research, 273*, 62 - 77. https://doi.org/10.1016/j.schres.2022.08.027

Ni, P., & Chung, S. (2020). Mitochondrial Dysfunction in Schizophrenia. *BioEssays, 42*. https://doi.org/10.1002/bies.201900202

Nunes, P., Benjamin, S. R., De Sousa Brito, R., De Aguiar, M. R., Neves, L. B., & De Bruin, V. S. D. (2025). Mitochondria, Oxidative Stress, and Psychiatric Disorders: An Integrative Perspective on Brain Bioenergetics. *Clinical Bioenergetics*. https://doi.org/10.3390/clinbioenerg1010006

Ortiz-González, X. R. (2021). Mitochondrial Dysfunction: A Common Denominator in Neurodevelopmental Disorders?. *Developmental neuroscience, 43*, 222 - 229. https://doi.org/10.1159/000517870

Payares, D. P. V., Spooner, L., Vosters, J. A., Domínguez, S., Patrick, L., Harris, A., & Kanungo, S. (2024). A systematic review on the role of mitochondrial dysfunction/disorders in neurodevelopmental disorders and psychiatric/behavioral disorders. *Frontiers in Psychiatry, 15*. https://doi.org/10.3389/fpsyt.2024.1389093

Pei, L., & Wallace, D. (2017). Mitochondrial Etiology of Neuropsychiatric Disorders. *Biological psychiatry, 83*, 722 - 730. https://doi.org/10.1016/j.biopsych.2017.11.018

Ricci, V., Martinotti, G., Mosca, A., & Maina, G. (2026). Bioenergetic impairment in schizophrenia: role of mitochondrial signaling in synaptic dysfunction - a systematic review. *Frontiers in Cell and Developmental Biology, 14*. https://doi.org/10.3389/fcell.2026.1740079

Tanaka, M., Szabó, Á., Spekker, E., Polyák, H., Tóth, F., & Vécsei, L. (2022). Mitochondrial Impairment: A Common Motif in Neuropsychiatric Presentation? The Link to the Tryptophan–Kynurenine Metabolic System. *Cells, 11*. https://doi.org/10.3390/cells11162607

Valenti, D., & Vacca, R. A. (2023). Brain Mitochondrial Bioenergetics in Genetic Neurodevelopmental Disorders: Focus on Down, Rett and Fragile X Syndromes. *International Journal of Molecular Sciences, 24*. https://doi.org/10.3390/ijms241512488

Yang, Z., Luo, Y., Yang, Z., Liu, Z., Li, M., Wu, X., Chen, L., & Xin, W. (2025). Mitochondrial dynamics dysfunction and neurodevelopmental disorders: From pathological mechanisms to clinical translation. *Neural Regeneration Research, 21*, 1926 - 1946. https://doi.org/10.4103/nrr.nrr-d-24-01422